Towa to proactively expand
Entering new markets, including the US, through partnerships forms a key part of Towa Pharmaceutical’s ‘Proactive’ medium-term business plan. Editor Aidan Fry examines the Japanese generics specialist’s growth strategy.
You may also be interested in...
Japan’s Towa has struck a deal to acquire the Pensa Investments generics division of Spain’s Esteve in an all-cash transaction worth €320m. The acquisition gives Towa access to the Spanish market as well as subsidiaries in Europe and the US.
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.